drugset / Trial / NCT01207908

Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy

NCT01207908

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle function in Duchenne Muscular Dystrophy (DMD).

Timeline

Start
2010-11
Primary completion
2012-10
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject mecasermin Protein / enzyme biologic Subcutaneous